SL-1-29

SL-1-29 is an investigational, second-generation flexible heteroarotinoid (Flex-Het) analog derived from the parental compound SHetA2. It is the (R)-enantiomer of the racemic mixture SL-1-09 (1-(1-(naphthalen-1-yl)ethyl)-3-(4-nitrophenyl)thiourea). Developed by researchers at Touro University and Dominican University of California, SL-1-29 was designed to retain the anti-cancer properties of SHetA2 while exhibiting lower lipophilicity to improve oral bioavailability and reduce potential liver toxicity. In preclinical studies evaluating breast cancer cell lines (including ERα+ and ERα- subtypes), SL-1-29 demonstrated growth inhibitory effects, although it was found to be less potent than its corresponding (S)-enantiomer, SL-1-30.

Other names

(R)-1-(1-(naphthalen-1-yl)ethyl)-3-(4-nitrophenyl)thiourea(R)-SL-1-09